Join the club for FREE to access the whole archive and other member benefits.

BioMoti

Company that engineers cancer therapeutics

We are developing #Oncojans, a promising new class of drug-loaded particles, designed to precisely target and gain entry to cancer cells. In the tumours, they slowly release drugs at the point of need whilst sparing healthy tissue. Early preclinical studies for #BMT101, our lead ovarian cancer candidate, compared to the clinical standard of care, Taxol®, have shown very encouraging results including over 10-fold increases in drug concentration in tumours, 65-fold reductions in tumour burden, 4-fold increases in survival and loss of toxicity. #BMT101 and future engineered #Oncojans could be transformational in the treatment of cancer patients.

Visit website: https://www.biomoti.com/

 biomoti

 BioMoti

Details last updated 20-Sep-2019

Topics mentioned on this page:
Cancer